Best melanotan 2: Frequently asked questions

MT2 will produce pigmentation without UV, but expect a longer timeline (6–8 weeks vs 3–4 weeks) and less uniform tan distribution. The peptide stimulates melanogenesis, but without UV-induced melanin oxidation, the tan appears lighter and more yellowish-brown than the deep brown achieved with UV synergy. Some users prefer this approach to avoid UV-related skin aging, accepting the trade-off in tan depth.

Resume at the dose you were using before the missed day. Do not double-dose to 'catch up.' Loading phases establish receptor priming gradually; a single missed day does not reset progress. If you miss 3+ consecutive days, restart the loading phase from 0.25mg to re-establish receptor adaptation without triggering acute nausea from a higher dose after a gap.

Daily low-dose protocols (0.5mg or less) sustained over weeks to months produce cumulative melanocortin receptor effects, including baseline libido elevation and increased spontaneous sexual ideation. But they also accelerate skin pigmentation, which becomes permanent with prolonged use. No long-term safety data exists for MT-2 beyond 16 weeks of continuous administration in clinical trials. Cycling protocols (e.g., 4 weeks on, 2 weeks off) are commonly used in research settings to mitigate cumulative side effects, though the optimal cycle length for libido maintenance has not been formally studied.

This indicates melanocortin receptor downregulation from chronic stimulation. Discontinue MT-2 for 2–4 weeks to allow receptor density to normalise, then resume at a lower frequency (2×/week maximum instead of daily or every-other-day). Chronic daily dosing is the primary driver of tolerance development. Intermittent protocols maintain sensitivity indefinitely in most cases.

Reduce to 0.25mg daily and extend the loading phase to 14–21 days. Nausea severity correlates with dose escalation speed. Slower titration allows MC4R desensitization, reducing gastrointestinal distress. Take the injection with food and avoid dosing within three hours of vigorous physical activity, which amplifies nausea through increased gut motility. If nausea persists beyond one week at 0.25mg, Melanotan-2 may not be tolerable at any therapeutic dose.

Administer MT-2 on an empty stomach or with a small protein-based snack (not high-fat meals, which delay absorption) and consider splitting the daily dose into two smaller injections 8–12 hours apart to reduce peak plasma concentration. Nausea is MC4R-mediated and dose-dependent. If it persists beyond the first week of consistent dosing, reduce your dose by 25–50%. Ginger supplementation (1g) taken 30 minutes before injection reduces nausea severity in approximately 40% of users based on small observational studies, though this is not a substitute for dose reduction if symptoms are severe.

Discontinue use immediately if an erection lasts longer than two hours or becomes painful. This is a melanocortin-mediated effect that can progress to priapism, a medical emergency requiring intervention to prevent permanent tissue damage. Prolonged erections occur in approximately 8–12% of male users at doses above 1.5mg and are rare below 1.0mg. If you're experiencing this at lower doses, it may indicate heightened MC4R sensitivity; future protocols should use half the dose or discontinue MT-2 entirely in favour of alternative approaches.

This is expected receptor desensitisation. MC4R downregulates under sustained agonist exposure, reducing the satiety signal even at the same dose. Take a 4-week washout period with zero MT-2 administration to restore receptor density, then resume at your previous effective dose. Alternatively, switch to alternate-day dosing (0.5mg every 48 hours) to slow desensitisation. Some research protocols maintain efficacy for 12–16 weeks using this approach. Avoid escalating the dose above 0.75mg to 'chase' the effect; higher doses won't overcome desensitisation and only increase side effect burden.

Reduce the dose by 50% and re-titrate more gradually. Persistent nausea beyond 7 days indicates MC1R activation in the area postrema is too strong relative to MC4R benefit. Drop to 0.125mg daily for 5 days, then increase to 0.25mg if tolerated. Some researchers split the daily dose into two 0.125mg injections (morning and early afternoon) to smooth the plasma concentration curve and reduce peak nausea. If nausea persists at 0.125mg, MT-2 may not be suitable. The compound's nausea profile is receptor-mediated and dose-dependent, meaning tolerance doesn't develop the way it does with GLP-1 agonists.

Reduce dose by 0.25mg and administer with food in the stomach to buffer initial melanocortin stimulation of gastric receptors. Nausea results from off-target MC3R activation in the gastrointestinal tract. It is dose-dependent and typically resolves within 30–60 minutes. If nausea persists at doses below 0.5mg, MC4R agonists may not be suitable; the side effect profile outweighs benefit at that threshold.

Increase to 0.5mg daily after 5–7 days at the starting dose. Approximately 30% of individuals require the higher end of the therapeutic range to achieve noticeable satiety changes. If 0.5mg produces no effect after 10 days, you may be a non-responder. MT-2 efficacy at MC4R varies based on endogenous melanocortin tone and receptor polymorphisms that aren't predictable without genetic screening. Non-responders should consider alternative peptide pathways rather than escalating MT-2 beyond 0.75mg, as higher doses shift the effect profile toward tanning and nausea without proportional appetite benefit.

Reduce your dose to 0.25mg daily and extend the loading phase by one to two weeks. Nausea results from MT2's binding to MC3 and MC4 receptors in the hypothalamus, which regulate appetite and nausea signaling. This effect diminishes as melanocyte upregulation occurs and more peptide is sequestered at MC1R sites. Administering the injection at night before bed allows you to sleep through peak nausea, which occurs 1–3 hours post-injection.

Restart with a mini-loading phase at 0.25mg for 3 days before resuming maintenance. Skipping more than 10 days of maintenance injections allows melanocyte receptor expression to return to baseline. Jumping straight to 1.0mg after a gap causes the same side effects as initial dosing. A compressed reload (3 days at 0.25mg) re-primes receptors without full reset. UV exposure during the reload accelerates pigmentation recovery.

Increase to 1.25mg on the next administration and assess response. Some individuals require 1.5–2mg to saturate MC4R receptors sufficiently for measurable erectile effects due to lower baseline receptor density. If no response occurs at 2mg after three separate administrations, melanocortin pathway responsiveness may be limited. This occurs in approximately 15–20% of users, often correlated with polymorphisms in MC4R gene expression. Alternative pathways (nitric oxide donors, PDE5 inhibitors) would be the next consideration.

Discard it immediately. Cloudiness indicates bacterial contamination or peptide aggregation, both of which render the solution unsafe and ineffective. Melanotan-2 in bacteriostatic water should remain clear and colorless. Yellow, brown, or opaque solutions signal protein denaturation or microbial growth. Never inject cloudy peptides under any circumstance. The risk of infection outweighs any potential tanning benefit.

Resume at the last tolerated dose rather than restarting at 0.25mg. Missing doses during loading delays visible pigmentation by 5–7 days but does not reset receptor upregulation entirely. MC1R density remains elevated for 48–72 hours post-injection, so a three-day gap reduces cumulative activation without erasing progress. Continue the loading phase for an additional 3–5 days to compensate for missed exposures.

Pigmentation will begin to fade gradually but not disappear entirely within one week. Resume your twice-weekly maintenance schedule immediately. Do not attempt to 'catch up' by doubling your next dose, as this increases side effects without recovering lost pigmentation faster. If pigmentation has visibly faded after a two-week gap, a brief mini-loading phase (0.5mg daily for 5–7 days) can restore depth before returning to maintenance dosing.

Reduce initial dose to 0.1mg and extend loading phase to 10 days. Nausea and facial flushing result from MC4R activation in the hypothalamus and brainstem, not MC1R. These effects are dose-dependent and subside with repeated exposure (receptor desensitisation). Splitting doses. 0.1mg morning and 0.1mg evening. Distributes plasma peaks and reduces acute side effects. Avoid dosing on an empty stomach; MT-2 absorbed in the presence of food triggers less pronounced nausea.

Increase UV exposure duration before escalating dose. Most 'non-responders' aren't MT-2-resistant. They're under-exposing to UV. Melanotan-2 primes melanocytes but doesn't synthesise melanin without photostimulation. If you've injected 0.25mg daily for 7 days with minimal pigmentation, extend UV sessions from 10 minutes to 15–20 minutes (or add a second weekly session) before increasing MT-2 dose. Receptor priming takes 5–7 days; visible pigmentation lags behind enzyme upregulation by another 7–10 days.

Increase the dose incrementally by 0.25mg every 3–5 days until you reach the minimum effective dose that produces noticeable arousal changes. For most individuals, this falls between 0.5–1.0mg. Avoid jumping directly to higher doses based on anecdotal recommendations, as MC4R receptor sensitivity varies widely between individuals. Some users report delayed onset of libido effects, with maximal response appearing after 7–10 days of daily dosing due to cumulative receptor occupancy, so evaluate efficacy over a full week at each dose before escalating.